5-HT1A Partial Agonist Tandospirone for Behavioral and Psychological Symptoms in Oldest-old Patients with Dementia at a Special Elderly Nursing Home
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: To investigate the efficacy of tandospirone, an azapirone anxiolytic similar to buspirone that is used in Japan, for behavioral and psychological symptoms of dementia (BPSD), especially in oldest-old patients. Methods: This was an open-label observational study involving residents with BPSD in a special elderly nursing home between August 2013 and August 2018. The severity of dementia was assessed using the Clinical Dementia Rating (CDR) scale; as the main outcomes, the severity of BPSD was assessed using the Clinical Global Impressions-Severity scale (CGI-S) and Neuropsychiatric Inventory-12 (NPI-12) at baseline and 4 weeks after the maintenance dose of tandospirone was reached. The administration of tandospirone started at 30 mg, divided into three doses per day. Two weeks later, if the efficacy was sufficient based on the clinical nursing record, that dose was continued; if the efficacy was insufficient, the daily dose was increased from 40 mg/day to a maximum dose of 60 mg/day. Results: Thirty-three participants (25 females [76%], mean age 87.1 ± 5.4 years) completed the study. Twenty-three participants (70%) were oldest-old (18 females [78%], mean age 89.9 ± 3.4 years). The mean CDR score was 2.9 ± 0.3 in all participants. Tandospirone treatment showed few or no obvious adverse effects and significantly improved CGI-S scores, as well as total scores and many subscale scores on the NPI-12, in both the sample at large and the oldest-old participants. Conclusion: This study demonstrated the efficacy and safety of tandospirone for BPSD in oldest-old participants.
Abstract
Objective: To investigate the efficacy of tandospirone, an azapirone anxiolytic similar to buspirone that is used in Japan, for behavioral and psychological symptoms of dementia (BPSD), especially in oldest-old patients. Methods: This was an open-label observational study involving residents with BPSD in a special elderly nursing home between August 2013 and August 2018. The severity of dementia was assessed using the Clinical Dementia Rating (CDR) scale; as the main outcomes, the severity of BPSD was assessed using the Clinical Global Impressions-Severity scale (CGI-S) and Neuropsychiatric Inventory-12 (NPI-12) at baseline and 4 weeks after the maintenance dose of tandospirone was reached. The administration of tandospirone started at 30 mg, divided into three doses per day. Two weeks later, if the efficacy was sufficient based on the clinical nursing record, that dose was continued; if the efficacy was insufficient, the daily dose was increased from 40 mg/day to a maximum dose of 60 mg/day. Results: Thirty-three participants (25 females [76%], mean age 87.1 ± 5.4 years) completed the study. Twenty-three participants (70%) were oldest-old (18 females [78%], mean age 89.9 ± 3.4 years). The mean CDR score was 2.9 ± 0.3 in all participants. Tandospirone treatment showed few or no obvious adverse effects and significantly improved CGI-S scores, as well as total scores and many subscale scores on the NPI-12, in both the sample at large and the oldest-old participants. Conclusion: This study demonstrated the efficacy and safety of tandospirone for BPSD in oldest-old participants.
참고문헌 (38)
- Scheltens P, "Alzheimer’s disease", Lancet, 388, pp.505~517 (2016)
- Kawagoe T, "Developing and validating the Japanese version of Dimensional Apathy Scale(J-DAS)", Psychiatry Clin Neurosci, 74, pp.411~412 (2020)
- Gerlach LB, "Managing behavioral and psychological symptoms of dementia", Psychiatr Clin North Am, 41, pp.127~139 (2018)
- Lawlor BA, "Behavioral and psychological symptoms in dementia: the role of atypical antipsychotics", J Clin Psychiatry, 65(Suppl 11), pp.5~10 (2004)
- Yoneyama S, "Relationship of neighborly ties with cognitive decline and total mood disturbances in older adult residents of depopulated areas in Japan : The Ninchisho(Dementia)Supporter Caravan Himi Study", Psychiatry Clin Neurosci, 73, pp.763~765 (2019)
- Fam J, "Mindfulness practice alters brain connectivity in community-living elders with mild cognitive impairment", Psychiatry Clin Neurosci, 74, pp.257~262 (2020)
- Brodaty H, "Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia", Am J Psychiatry, 169, pp.946~953 (2012)
- Jeste DV, "ACNP White Paper : update on use of antipsychotic drugs in elderly persons with dementia", Neuropsychopharmacology, 33, pp.957~970 (2008)
- Arai H, "Mortality risk in current and new antipsychotic Alzheimer’s disease users : large scale Japanese study", Alzheimers Dement, 12, pp.823~830 (2016)
- Nielsen RE, "Effects of antipsychotics on secular mortality trends in patients with Alzheimer’s disease", J Clin Psychiatry, 79, pp.17~ (2018)
- Poly TN, "Association between benzodiazepines use and risk of hip fracture in the elderly people : a meta-analysis of observational studies", Joint Bone Spine, 87, pp.241~249 (2020)
- Biswa Ranjan Mishra, "Donepezil for Compulsive Behavior in Degenerative Dementia: Case Series", Clinical Psychopharmacology and Neuroscience, 16(2), pp.224~227 (2018), 대한정신약물학회[DOI]
- Cadieux RJ, "Azapirones : an alternative to benzodiazepines for anxiety", Am Fam Physician, 53, pp.2349~2353 (1996)
- Barradell LB, "Tandospirone", CNS Drugs, 5, pp.147~153 (1996)
- Cantillon M, "Buspirone vs. haloperidol: a double-blind trial for agitation in a nursing home population with Alzheimer’s disease", Am J Geriatr Psychiatry, 4, pp.263~267 (1996)
- Masuda Y, "Effect of serotonin 1A agonist tandospirone on depression symptoms in senile patients with dementia", Hum Psychopharmacol, 17, pp.191~193 (2002)
- Sato S, "A preliminary open-label study of 5-HT1A partial agonist tandospirone for behavioural and psychological symptoms associated with dementia", Int J Neuropsychopharmacol, 10, pp.281~283 (2007)
- Ochi S, "Dose-dependent efficacy of tandospirone for an oldest-old patient with behavioral and psychological symptoms of dementia", J Clin Psychopharmacol, 39, pp.176~178 (2019)
- McKhann G, "Clinical diagnosis of Alzheimer’s disease : report of the NINCDS-ADRDA Work Group under the auspices of department of Health and Human Services task force on Alzheimer’s disease", Neurology, 34, pp.939~944 (1984)
- Román GC, "Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop", Neurology, 43, pp.250~260 (1993)
- McKeith IG, "Diagnosis and management of dementia with Lewy bodies : third report of the DLB Consortium", Neurology, 65, pp.1863~1872 (2005)
- McKeith IG, "Diagnosis and management of dementia with Lewy bodies : fourth consensus report of the DLB Consortium", Neurology, 89, pp.88~100 (2017)
- Morris JC, "The Clinical Dementia Rating(CDR) : current version and scoring rules", Neurology, 43, pp.2412~2414 (1993)
- Busner J, "The clinical global impressions scale:applying a research tool in clinical practice", Psychiatry(Edgmont), 4, pp.28~37 (2007)
- Cummings JL, "The Neuropsychiatric Inventory : assessing psychopathology in dementia patients", Neurology, 48(5Suppl 6), pp.S10~S6 (1997)
- Faul F, "G*Power 3 : a flexible statistical power analysis program for the social, behavioral, and biomedical sciences", Behav Res Methods, 39, pp.175~191 (2007)
- Lai MK, "Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease", Brain Res, 974, pp.82~87 (2003)
- Lai MK, "Differential involvement of hippocampal serotonin1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimer’s disease", Psychopharmacology(Berl), 213, pp.431~439 (2011)
- Verdurand M, "Hippocampal 5-HT1A receptor expression changes in prodromal stages of Alzheimer’s disease:beneficial or deleterious?", Neuropharmacology, 123, pp.446~454 (2017)
- Islam MR, "Rivastigmine improves hippocampal neurogenesis and depression-like behaviors via 5-HT1A receptor stimulation in olfactory bulbectomized mice", Neuroscience, 272, pp.116~130 (2014)
- Afshar S, "The effect of NAD-299 and TCB-2 on learning and memory, hippocampal BDNF levels and amyloid plaques in Streptozotocininduced memory deficits in male rats", Psychopharmacology(Berl), 235, pp.2809~2822 (2018)
- Afshar S, "Protective effects of 5-HT1A receptor antagonist and 5-HT2A receptor agonist on the biochemical and histological features in a rat model of Alzheimer’s disease", J Chem Neuroanat, 96, pp.140~147 (2019)
- Nishitsuji K, "Tandospirone in the treatment of generalised anxiety disorder and mixed anxiety-depression : results of a comparatively high dosage trial", Clin Drug Investig, 24, pp.121~126 (2004)
- Kishi T, "Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists : a meta-analysis", Int J Neuropsychopharmacol, 16, pp.1259~1266 (2013)
- Nishitsuji K, "The pharmacokinetics and pharmacodynamics of tandospirone in rats exposed to conditioned fear stress", Eur Neuropsychopharmacol, 16, pp.376~382 (2006)
- Uehara T, "Chronic treatment with tandospirone, a 5-HT(1A)receptor partial agonist, suppresses footshock stress-induced lactate production in the prefrontal cortex of rats", Pharmacol Biochem Behav, 113, pp.1~6 (2013)
- FDG PET hypometabolism within the default mode network in Alzheimer’s disease, "Eur J Nucl Med Mol Imaging", 2016, 2040~2049
- "Abridged Life Tables for Japan 2018" (2018)[URL]